Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.75
0.112.37%
At close: May 15, 5:00 PM EST
$4.75
N/A
After Hours: 5:02 PM EST
AN2 Therapeutics Inc Analyst Ratings
ANTXNASDAQ
Earnings: Q1 2026 Earnings were released on Mon May 11th, after the market close
AN2 Therapeutics Analyst Ratings and Price Targets | NASDAQ:ANTX | Benzinga
AN2 Therapeutics Inc has a consensus price target of $4.5 based on the ratings of 6 analysts. The high is $9 issued by Leerink Partners on May 14, 2026. The low is $2 issued by JMP Securities on May 5, 2025. The 3 most-recent analyst ratings were released by Leerink Partners, JMP Securities, and Citizens Capital Markets on May 14, 2026, May 5, 2025, and March 26, 2025, respectively. With an average price target of $5.33 between Leerink Partners, JMP Securities, and Citizens Capital Markets, there's an implied 12.28% upside for AN2 Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
JMP Securities
Citizens Capital Markets
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for AN2 Therapeutics
Loading calendar...
FAQ
What is the target price for AN2 Therapeutics (ANTX) stock?
The latest price target for AN2 Therapeutics (NASDAQ:ANTX) was reported by Leerink Partners on May 14, 2026. The analyst firm set a price target for $9.00 expecting ANTX to rise to within 12 months (a possible 89.47% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AN2 Therapeutics (ANTX)?
The latest analyst rating for AN2 Therapeutics (NASDAQ:ANTX) was provided by Leerink Partners, and AN2 Therapeutics upgraded their outperform rating.
When was the last upgrade for AN2 Therapeutics (ANTX)?
The last upgrade for AN2 Therapeutics Inc happened on May 14, 2026 when Leerink Partners raised their price target to $9. Leerink Partners previously had a market perform for AN2 Therapeutics Inc.
When was the last downgrade for AN2 Therapeutics (ANTX)?
The last downgrade for AN2 Therapeutics Inc happened on November 18, 2024 when TD Cowen changed their price target from N/A to N/A for AN2 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for AN2 Therapeutics (ANTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AN2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AN2 Therapeutics was filed on May 14, 2026 so you should expect the next rating to be made available sometime around May 14, 2027.
Is the Analyst Rating AN2 Therapeutics (ANTX) correct?
While ratings are subjective and will change, the latest AN2 Therapeutics (ANTX) rating was a upgraded with a price target of $0.00 to $9.00. The current price AN2 Therapeutics (ANTX) is trading at is $4.75, which is within the analyst’s predicted range.
